A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child ...

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.

Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor ...

An experimental gene-editing treatment shows promise for permanently lowering levels of cholesterol and triglycerides, ...

Study shows gene editing restores drug sensitivity by targeting NRF2, with potential across multiple tumor types.

In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the ...

CRISPR Therapeutics AG (NASDAQ: CRSP) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, ...

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the ...

Explore CRISPR technology explained, gene editing science, DNA modification, and genetic engineering ethics—discover how ...

Genetic medicines-focused Scribe Therapeutics is racing toward the clinic on the heels of a preclinical data drop for three ...

According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...